Under way, not recruiting
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
NCT05108870 · University of Chicago · Updated 24 April 2026
- What is being tested
- HB-201; HB-202; Carboplatin; Paclitaxel; Transoral Robotic Surgery
- For
- Human Papilloma Virus; HPV; HPV Positive Oropharyngeal Squamous Cell Carcinoma; Head and Neck Cancer
- Kind of study
- Tests a treatment or device on volunteers. Phase 1 and Phase 2.
- Who can join
- Ages 18 years and older. About 35 people. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started 22 Aug 2022, ends 1 Jan 2027. Registered 5 Nov 2021.
- Results
- None posted yet.
In the researchers' words
Doctors leading this study hope to learn about the safety and effectiveness of combining medications HB-201 and HB-202 (also known as TheraT® vectors) with chemotherapy using carboplatin and paclitaxel in the beginning of the study (induction) and if combining these medications can increase tumor shrinkage after therapy and reduce the amount of radiotherapy and chemotherapy that will later be needed. In addition, the study is looking at ways to reduce side effects overall using robotic surgery, chemotherapy and radiotherapy, or radiotherapy alone. Your participation in this research will last about 2 years. HB-201 and HB-202 are experimental (meaning the US Food and Drug Administration (FDA) has not approved these drugs), and therefore they can only be given in a research study.
Sites
- University of ChicagoChicago, Illinois, United States